

MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postars as Express Mail (EV662451823US) in an envelope addressed to: Commissioner

for Patents, P.O. Box 1450, Alexandria, VA 22313/1450 on

16 May 2005 Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

rinted Name

Applicants:

Laird and Eads

Serial No.:

09/825,566

Filing Date:

April 2, 2001

For: EPIGENETIC SEQUENCES FOR ESOPHAGEAL ADENOCARCINOMA

Art Unit:

1634

Examiner:

Jehanne Souaya Sitton

Docket No.:

47675-18

Date:

May 16, 2005

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements in 37 C.F.R. § 1.56, and in conformance with 37 C.F.R. 1.97 and 1.98, Applicants hereby submit a Supplemental Information Disclosure Statement.

Applicants respectfully request that the Examiner: (1) consider the following documents during the course of his or her examination of the above-identified patent application, and (2) list the following documents in the References Cited section of any patent that may issue from the above-identified patent application.

Applicants cite 11 references listed on the attached forms. The order of these references

should not be construed to suggest their relative pertinence. The Examiner is encouraged to review the entire disclosure of each reference in order to draw his or her own conclusions concerning the pertinence of the references to the claimed subject matter of this application. The filing of this Information Disclosure Statement should not be construed to suggest that a patentability search has been made or that the cited references are prior art or are considered to be material to patentability.

These documents came to the attention of the Applicants through two European Search Reports issued in a related European application. Copies of these Search Reports are also included.

Applicants respectfully request consideration of the foregoing documents during examination of the above-identified patent application. Applicants have enclosed a completed Information Disclosure Statement by Applicant and copies of the non-US patent and non-patent literature documents.

A check in the amount of \$180 is enclosed. The Commissioner is authorized to charge any additional fees deemed due or to credit and overpayment to Deposit Account 04-0258 of Davis Wright Tremaine LLP. A copy of this document is enclosed.

Respectfully submitted,

Davis Wright Tremaine L

Rarry L. Davison, Ph.D., J.D.

Attorney for Applicants Registration No. 47,309

2

Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Telephone: (206) 628-7621 Facsimile: (206) 628-7699

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known			
Application Number	09/825,566		
Filing Date	April 2, 2001		
First Named Inventor	Laird		
Art Unit	1634		
Examiner Name	Jehanne S. Sitton		
Attorney Docket Number	47675-18		

	U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	 	US-	<u> </u>			
		05-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
	†	US-				
		US-	 			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	F1	WO 00/70090	11/23/2000	USC		
		414		· · · · · · · · · · · · · · · · · · ·		_
	ļ					<u>L</u>

			44.4	
Examiner		Date		
Signature		Considered		
			5	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute or form 1449/PTO	Complete if Known		
BADE	Application Number	09/825,566	
INFORMATION DISCLOSURE	Filing Date	April 2, 2001	
STATEMENT BY APPLICANT	First Named Inventor	Laird	
(Use as many sheets as necessary)	Art Unit	1634	
(Use as many sneets as necessary)	Examiner Name	Jehanne S. Sitton	
Sheet 2 of 2	Attorney Docket Number	47675-18	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	WONG et al., "P16-INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas," Cancer Research, 57(13): 2619-2622 1997	
	17	KLUMP et al., "Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus," Gastroenterology 115(6):1381-1386, 1998	
	18	KEMPSTER et al., "Methylation of exon 2 of p16 is associated with late stage oesophageal cancer," Cancer Letters 150(1):57-26, 2000	
	19	XING et al., "Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China," Carcinogenesis 20(1):77-84, 1999	
	20	EADS et al., "CpG island hypermethylation in human colorectal tumors," Cancer Research 59(10):2302-2306, 1999	
	21	HILTUNEN et al., "Hypermethylation of the APC gene promoter region in human colorectal carcinoma," International Journal of Cancer 70(6):644-648, 1997	
	22	TOYOTA et al., "Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype," Cancer Research 59(21) 5438-5442, 1999	
	23	TSUCHIYA et al., "Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia," Oncogene 19(32):3642-3646, 2000	
	24	EADS et al., "Epigenetic patterns in the progression of esophageal adenocarcinoma," Cancer Research 61(8): 3410-3418, 2001	
	25	BACHMAN et al., "Methylation-associated silencing of the tissue inhibitor of Metalloproteinase-3 gene," Cancer Research 59(4):798-802, 1999	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.